ライフサイエンスコーパス: Lynch syndrome

1 ry to identify patients at high risk for the Lynch syndrome).

2 women with a mismatch repair gene mutation (Lynch syndrome).

3 ealthy intestinal tissues from patients with Lynch syndrome.

4 idelines for the management of patients with Lynch syndrome.

5 y for detection of adenomas in patients with Lynch syndrome.

6 nt of neoplasias and tumors in patients with Lynch syndrome.

7 n linked to many genetic diseases, including Lynch syndrome.

8 orectal cancer surveillance in patients with Lynch syndrome.

9 ously identified in individuals suspected of Lynch syndrome.

10 the MLH1 promoter are likely to be caused by Lynch syndrome.

11 patients or clinicians reduced detection of Lynch syndrome.

12 ce and prevention programs for patients with Lynch syndrome.

13 ipation rate among relatives at risk for the Lynch syndrome.

14 trategies for patients with colon cancer and Lynch syndrome.

15 Lynch syndrome, whereas its absence excludes Lynch syndrome.

16 arget susceptible to aberrant methylation in Lynch syndrome.

17 ven those meeting the strongest criteria for Lynch syndrome.

18 tions of this gene which are associated with Lynch syndrome.

19 adenoma and carcinoma among persons with the Lynch syndrome.

20 g appropriate cancer screening in women with Lynch syndrome.

21 l adenoma or carcinoma among carriers of the Lynch syndrome.

22 lar studies consistent with the diagnosis of Lynch syndrome.

23 eral salpingo-oophorectomy in women with the Lynch syndrome.

24 ncer is the most common cancer in women with Lynch syndrome.

25 ly diagnosed endometrial cancer patients had Lynch syndrome.

26 tic testing in a large population at risk of Lynch syndrome.

27 r genes, and terms related to the biology of Lynch syndrome.

28 metrial and ovarian cancer in women with the Lynch syndrome.

29 ance, but colorectal cancer was only seen in Lynch syndrome.

30 e classified as Lynch syndrome and 68 as non-Lynch syndrome.

31 a, hereditary breast and ovarian cancer, and Lynch syndrome.

32 seen major advances in the understanding of Lynch syndrome.

33 HNPCC may appropriately identify women with Lynch syndrome.

34 et either clinical or molecular criteria for Lynch syndrome.

35 ditary non-polyposis colon cancer (HNPCC) or Lynch syndrome.

36 nd young adults with previously unrecognised Lynch syndrome.

37 MSH2 genes found in patients with suspected Lynch syndrome.

38 H1 and MSH2 found in patients with suspected Lynch syndrome.

39 One family met diagnostic criteria for Lynch syndrome.

40 and DNA mismatch repair genes for suspected Lynch syndrome.

41 tumors and that 7% of cases had features of Lynch syndrome.

42 ally in sessile serrated adenomas/polyps and Lynch syndrome.

43 ssification of VUSs in genes associated with Lynch syndrome.

44 nts with double somatic colorectal tumors or Lynch syndrome.

45 tation spectrum, and risk of CRC in AAs with Lynch syndrome.

46 lel sequencing in individuals with suspected Lynch syndrome.

47 ith the most common inherited CRC condition, Lynch syndrome.

48 especially appealing goal for patients with Lynch syndrome.

49 that of individuals of European descent with Lynch syndrome.

50 stable (MSI-high), in one case associated to Lynch-syndrome.

51 y nonpolyposis colorectal cancer (HNPCC), or Lynch, syndrome.

52 tient illustrates two current concepts about Lynch syndrome: 1) adenomas are the cancer precursor and

53 Among the 23 probands with the Lynch syndrome, 10 were more than 50 years of age and 5

54 (83.3%) had at least 1 gene mutation: 37 had Lynch syndrome (13, MLH1 [including one with constitutio

55 th Lynch syndrome, 22 with mutation-negative Lynch syndrome, 16 with familial adenomatous polyposis,

56 of these patients had a mutation causing the Lynch syndrome (2.2 percent).

57 with 4 of 18 (22%) tumors from patients with Lynch syndrome, 2 of 10 (20%) tumors with MLH1 hypermeth

58 ereditary cancer syndrome, including 23 with Lynch syndrome, 22 with mutation-negative Lynch syndrome

59 ects had pathogenic variants associated with Lynch syndrome (25 with mutations in MSH2, 24 with mutat

60 All 4 patients with Lynch syndrome (3.1%) had a sequence variation in the ML

61 h confirmed cases of Lynch syndrome (SIR for Lynch syndrome, 6.04; 95% confidence interval [CI], 3.58

62 olyps--and tissue derived from patients with Lynch syndrome--78 low-grade dysplastic adenomas, 57 hig

63 High-risk individuals (eg, those with Lynch syndrome, a first-degree relative with CRC, or adv

64 the mismatch repair (MMR) genes, involved in Lynch syndrome, a frequent predisposition to colon and e

65 Lynch syndrome, a nonpolyposis form of hereditary colore

66 202 families meeting Amsterdam criteria for Lynch syndrome accounted for 2.6% of all colorectal canc

67 te instability (MSI), which is a hallmark of Lynch syndrome, activities must also exist that unwind s

68 ereditary nonpolyposis colorectal cancer (or Lynch syndrome) adds difficulty to its diagnosis, use of

69 , education and genetic counseling regarding Lynch syndrome (age 21 years).

70 Although the clinical phenotype of Lynch syndrome (also known as hereditary nonpolyposis co

71 lonoscopic surveillance for individuals with Lynch syndrome, although the optimal age at initiation a

72 orectal cancer to identify families with the Lynch syndrome, an autosomal dominant cancer-predisposit

73 Twenty-nine families were classified as Lynch syndrome and 68 as non-Lynch syndrome.

74 ent management of families suspected to have Lynch syndrome and demonstrates the value of multidiscip

75 A detailed explanation of Lynch syndrome and the methodology utilized to derive th

76 care for dMMR mCRCs including patients with Lynch syndrome and the more common sporadic cases.

77 cancers; 3% are of these are associated with Lynch syndrome and the other 12% are caused by sporadic,

78 for other cancers (eg, endometrial cancer in Lynch syndrome), and assess familial risk.

79 12 patients with genetic mutation leading to Lynch syndrome, and 13 patients with cancer.

80 ed cohort of 56 CMMRD, 8 suspected CMMRD, 40 Lynch syndrome, and 43 control blood samples were amplic

81 nts with known cases of polyposis syndromes, Lynch syndrome, and chronic inflammatory disease were ex

82 t-degree relatives with pancreas cancer with Lynch syndrome, and mutations in BRCA1, BRCA2, PALB2, an

83 ciated with sporadic MLH1ph rather than with Lynch syndrome, and these patients may be eligible for k

84 screening at-risk and affected persons with Lynch syndrome; and Table 12 lists the guidelines for th

85 lorectal cancer with and without evidence of Lynch syndrome are at equal risk of high-risk adenomas d

86 Patients with Lynch syndrome are at high risk for colon and endometria

87 Women in families with Lynch syndrome are less aware of their risks for extraco

88 he mutations reported as potentially causing Lynch syndrome are missense mutations in human mismatch

89 CRC in patients with a putative diagnosis of Lynch syndrome are scarcely defined, and many of them un

90 data describing cancer risks associated with Lynch syndrome are variable.

91 nt of patients at risk for and affected with Lynch syndrome as follows: Figure 1 provides a colorecta

92 ent 15% of all colorectal cancers, including Lynch syndrome as the most frequent hereditary form of t

93 tained clinical data from 2747 patients with Lynch syndrome associated with variants in MLH1, MSH2, o

94 l tumour bank we determine the prevalence of Lynch syndrome, associated cancer risks and pathogenicit

95 Individuals with a history of Lynch syndrome-associated cancer (odds ratio [OR], 0.1;

96 All patients had a history of Lynch syndrome-associated cancer and/or polyps.

97 cluded having a first-degree relative with a Lynch syndrome-associated cancer, endometrial tumor with

98 for endometrial cancer, and 25%-32% for any Lynch syndrome-associated cancer.

99 Lynch syndrome-associated cancers are amenable to survei

100 No elevated risk for non-Lynch syndrome-associated cancers was observed.

101 were calculated to estimate risks for other Lynch syndrome-associated cancers.

102 d type of mutation influence age at onset of Lynch syndrome-associated cancers.

103 trospective cohort study of individuals with Lynch syndrome-associated colorectal, endometrial, and/o

104 ion scheme to constitutional variants in the Lynch syndrome-associated genes MLH1, MSH2, MSH6 and PMS

105 can improve the likelihood of identifying a Lynch syndrome-associated germline mutation in MLH1, MSH

106 ge 50 years, 9% were found to carry germline Lynch syndrome-associated mutations.

107 amplification for 99 probands diagnosed with Lynch syndrome-associated tumors showing isolated loss o

108 We studied associations between Lynch syndrome-associated variants in MMR genes and risk

109 However, for patients with Lynch syndrome-associated variants of MSH6 or PMS2, late

110 starting at age 25 years for all carriers of Lynch syndrome-associated variants, regardless of gene p

111 120 with low and 74 with high likelihood of Lynch syndrome based on tumor molecular profile.

112 47 women, 136 had mutations in BRCA1, BRCA2, Lynch syndrome, BRIP1, and RAD51D genes, and 11 had a fa

113 lies with LLS is lower that of families with Lynch syndrome but higher than that of families with spo

114 PMS2 mutations contribute significantly to Lynch syndrome, but the penetrance for monoallelic mutat

115 rates a strategy for universal screening for Lynch syndrome by tumor testing of patients diagnosed wi

116 r PMS2) develop a rare but severe variant of Lynch syndrome called constitutional MMR deficiency (CMM

117 Amsterdam-positive (MSS HNPCC) (N = 22); (2) Lynch syndrome cancers (identified mismatch repair mutat

118 For all Lynch syndrome cancers combined, the intention-to-treat

119 Non-colorectal Lynch syndrome cancers were reported in 36 participants

120 Patients with Lynch syndrome carry germline mutations in single allele

121 Approximately 75% of patients with suspected Lynch syndrome carry variants in MLH1 or MSH2, proteins

122 A significant proportion of Lynch syndrome cases are believed to be due to large gen

123 This selective strategy missed 4.9% of Lynch syndrome cases but resulted in 34.8% fewer cases r

124 the analysis of 71 CRC cases suspected to be Lynch syndrome cases for MSH2, MLH1, MSH6, and PMS2 gene

125 g that sporadic cases can be admixed in with Lynch syndrome cases, even those meeting the strongest c

126 Lynch syndrome, caused by germline mutations in the mism

127 Lynch syndrome, clonal hematopoiesis, and cervical intra

128 reater sensitivity for the identification of Lynch syndrome compared with multiple alternative strate

129 Lynch syndrome confers increased risk for various malign

130 Individuals with known Lynch syndrome could be risk stratified by mutated gene

131 tumor testing to identify families with the Lynch syndrome could yield substantial benefits at accep

132 r of methylated markers (8.4), surprisingly, Lynch syndrome CRCs also demonstrated frequent methylati

133 n event not only in sporadic CRC but also in Lynch syndrome CRCs.

134 In patients with Lynch syndrome, CRCs can develop via different pathways.

135 Among people with Lynch syndrome, current smokers have an increased risk o

136 While patients with Lynch syndrome develop a rare "medullary" variant of ade

137 55.7 months [SD 31.4]) for participants with Lynch syndrome enrolled into a randomised trial of daily

138 ting for mismatch repair (MMR) deficiency in Lynch syndrome establishing a new paradigm, combinatoria

139 well-defined inherited syndromes, including Lynch syndrome, familial adenomatous polyposis, MUTYH-as

140 A diagnosis of Lynch syndrome, familial adenomatous polyposis, or anoth

141 utations in MSH2 have been reported in a few Lynch syndrome families that lacked germline mutations i

142 s who underwent clinical genetic testing for Lynch syndrome from 2012 through 2013.

143 cal and DNA sequence data from patients with Lynch syndrome from 3 countries, we associated pathogeni

144 hed MMRd neoplastic lesions of patients with Lynch syndrome from FAP controls.

145 Evaluation with an NGS panel that included Lynch syndrome genes and other genes associated with hig

146 ghly penetrant CRCP syndromes in addition to Lynch syndrome genes as a first-line test is likely to p

147 ian cancer genes (CHEK2, ATM, and PALB2) and Lynch syndrome genes.

148 al option for patients with colon cancer and Lynch syndrome, goals of treatment are to maximize life

149 Increased screening for Lynch syndrome has identified patients with tumors that

150 Individuals with Lynch syndrome have a high risk of developing colorectal

151 asia; however, the effects of aspirin in the Lynch syndrome (hereditary nonpolyposis colon cancer) ar

152 In Lynch syndrome (hereditary nonpolyposis colon cancer), a

153 s is often used as a screening criterion for Lynch syndrome (hereditary nonpolyposis colorectal cance

154 Women with the Lynch syndrome (hereditary nonpolyposis colorectal cance

155 Lynch syndrome (hereditary nonpolyposis colorectal cance

156 SH6, and PMS2 lead to the development of the Lynch syndrome (hereditary nonpolyposis colorectal cance

157 e, familial atypical multiple mole melanoma, Lynch syndrome (hereditary nonpolyposis colorectal cance

158 h hereditary nonpolyposis colorectal cancer (Lynch syndrome, HNPCC) and a significant proportion of s

159 he DNA mismatch repair (MMR) gene MSH2 cause Lynch syndromes I and II and sporadic colorectal cancers

160 ients with colorectal adenocarcinoma for the Lynch syndrome identified mutations in patients and thei

161 Identifying families at high risk for the Lynch syndrome (ie, hereditary nonpolyposis colorectal c

162 nt of the neoplasms arising in patients with Lynch syndrome III, mice deficient in MSH6 die premature

163 and desirability of molecular screening for Lynch syndrome in all endometrial cancer patients.

164 The prevalence of Lynch syndrome in patients with LUS endometrial carcinom

165 hniques are available to identify hereditary Lynch syndrome in people with newly diagnosed colorectal

166 t fulfill the Amsterdam I or II criteria for Lynch syndrome in the Utah population and investigate th

167 Multiple adenomas were only seen in non-Lynch syndrome individuals (13/197; 6.6%), Fisher exact

168 Cancer was observed only in Lynch syndrome individuals (4/91; 4.4%), Fisher exact te

169 igh-risk adenomas occurred in 7 of 91 (7.7%) Lynch syndrome individuals and 15 of 197 (7.6%) non-Lync

170 Therefore non-Lynch syndrome individuals do require colonoscopic surve

171 Lynch syndrome individuals require short surveillance in

172 yndrome individuals and 15 of 197 (7.6%) non-Lynch syndrome individuals, adjusted relative risk 1.15

173 The population prevalence of Lynch syndrome is 0.442%.

174 Lynch syndrome is a hereditary cancer syndrome associate

175 Lynch syndrome is an autosomal dominant predisposition t

176 Lynch syndrome is an inherited cause of colorectal cance

177 Lynch syndrome is associated with an increased risk of c

178 Lynch syndrome is associated with inherited germline mut

179 Lynch syndrome is caused by dominantly inherited germlin

180 Lynch syndrome is caused by germline mutations in the mi

181 Lynch syndrome is caused by variants in DNA mismatch rep

182 Lynch syndrome is caused primarily by mutations in the m

183 The identification of individuals with Lynch syndrome is desirable because they can benefit fro

184 If MMR deficiency consistent with Lynch syndrome is detected, it should be communicated to

185 ied as mutated in an individual suspected of Lynch syndrome is listed as critical in such a reverse d

186 A universal screening strategy for Lynch syndrome is potentially effective because the over

187 Tumor screening for Lynch syndrome is recommended in all or most patients wi

188 vention of colorectal cancer with aspirin in Lynch syndrome is supported by our results.

189 Lynch syndrome is the most common form of hereditary col

190 Lynch syndrome is the most common hereditary colorectal

191 Lynch syndrome is the most common hereditary form of col

192 r; however, the risk of pancreatic cancer in Lynch syndrome is uncertain and not quantified.

193 sis colorectal cancer (HNPCC), also known as Lynch syndrome, is caused by mutations in the mismatch r

194 We developed a mouse model of Lynch syndrome (Lgr5-CreERT2;Msh2(flox/-) mice) and foun

195 Our study sought to define the prevalence of Lynch syndrome (LS) among patients with ACC.

196 hereditary breast and ovarian cancer (HBOC), Lynch syndrome (LS) and familial hypercholesterolemia (F

197 ted for FH of hereditary PC (HPC), HBOC, and Lynch syndrome (LS) and for his own PC status.

198 Lynch syndrome (LS) arises in patients with pathogenic g

199 Purpose Most existing literature describes Lynch syndrome (LS) as a hereditary syndrome leading to

200 reduce colorectal cancer (CRC) incidence in Lynch syndrome (LS) by detecting and removing adenomas.

201 Lynch Syndrome (LS) carriers occasionally develop centra

202 onstrated in 16% of cases, and a presumptive Lynch Syndrome (LS) diagnosis was made in up to 14% of p

203 observed in 15 (21.1%) patients and affected Lynch Syndrome (LS) genes: MLH1 (n = 10), MSH6 (n = 2),

204 Persons with Lynch syndrome (LS) have high lifetime risk of developin

205 The best screening practice for Lynch syndrome (LS) in endometrial cancer (EC) remains u

206 Lynch Syndrome (LS) is a common genetic cancer condition

207 Lynch Syndrome (LS) is an autosomal dominant disease con

208 The current diagnostic testing algorithm for Lynch syndrome (LS) is complex and often involves multip

209 Identifying individuals with Lynch syndrome (LS) is highly beneficial.

210 Purpose Current Lynch syndrome (LS) prediction models quantify the risk

211 Lynch syndrome (LS) predisposes to endometrial cancer (E

212 ll colorectal cancers (CRCs) be screened for Lynch syndrome (LS) through microsatellite instability (

213 of the common cancer predisposition disorder Lynch syndrome (LS), also known as hereditary nonpolypos

214 In Lynch syndrome (LS), one of the most highly prevalent ca

215 s) define the Muir-Torre syndrome variant of Lynch syndrome (LS), which is associated with increased

216 r has been described as a component tumor of Lynch syndrome (LS), with tumors obtained from mutation

217 C) and endometrial cancer (EC) to screen for Lynch syndrome (LS)-associated cancer predisposition.

218 cal prediction models effectively screen for Lynch syndrome (LS)-associated colorectal cancer (CRC) a

219 ately focus colonoscopy use in families with Lynch syndrome (LS).

220 SI) are well-established tools to screen for Lynch syndrome (LS).

221 newly diagnosed colorectal cancer (CRC) for Lynch syndrome (LS).

222 thogenic mutations, including 33 (3.1%) with Lynch syndrome (LS).

223 are causative for the cancer predisposition Lynch syndrome (LS).

224 and March, 2005, 937 eligible patients with Lynch syndrome, mean age 45 years, commenced treatment,

225 For young (30-year-old) patients with Lynch syndrome, mean survival was slightly better with T

226 ch syndrome (microsatellite unstable) or non-Lynch syndrome (microsatellite stable).

227 ctal cancer history) to classify families as Lynch syndrome (microsatellite unstable) or non-Lynch sy

228 luded hereditary non-polyposis colon cancer, Lynch syndrome, microsatellite instability, mismatch rep

229 o compare them with those from patients with Lynch syndrome, MLH1-hypermethylated, or microsatellite-

230 ellent potential for preclinical modeling of Lynch syndrome, MMR-deficient tumors of other tissue typ

231 In individuals with suspected Lynch syndrome, multigene panel testing identified high-

232 e panel testing identified 114 probands with Lynch syndrome mutations (9.0%; 95% CI, 7.6%-10.8%) and

233 ns at risk were tested, and of these, 52 had Lynch syndrome mutations and 65 did not.

234 syndrome or were strongly suspected to have Lynch syndrome on the basis of tissue-based molecular as

235 ing that of other hereditary conditions like Lynch Syndrome or Familial Adenomatous Polyposis.

236 lifetime risk of colorectal cancer [such as Lynch syndrome or familial adenomatous polyposis]).

237 Defects in human mismatch repair genes cause Lynch syndrome or hereditary non-polyposis colorectal ca

238 rtially explain the MSH2 allele frequency in Lynch syndrome or hereditary nonpolyposis colorectal can

239 families that fulfill Amsterdam criteria for Lynch syndrome or hereditary nonpolyposis colorectal can

240 women with LUS tumors were confirmed to have Lynch syndrome or were strongly suspected to have Lynch

241 elatives with a mutation associated with the Lynch syndrome, particularly women, whose life expectanc

242 e for the clinical genetic identification of Lynch syndrome patients and families.

243 960s) and prophylactic surgeries, such as in Lynch syndrome patients begun in 1977.

244 Seven of the 10 Lynch syndrome patients did not meet any published crite

245 neoplasia, we investigated samples from 100 Lynch syndrome patients using 16S rRNA gene sequencing o

246 red frameshift mutations in MSI-H cancer and Lynch syndrome patients, suitable for the design of comm

247 ctal tissues that included both sporadic and Lynch syndrome patients.

248 angements in a large population of suspected Lynch syndrome patients.

249 alterations in hMLH1 and hMSH2 in suspected Lynch syndrome patients.

250 Lynch syndrome poses multiple cancer risks, yet attentio

251 re pooled from the German and Dutch national Lynch syndrome registries.

252 al or endometrial cancer who participated in Lynch syndrome screening studies in Ohio and were found

253 treatment of colon cancer in a patient with Lynch syndrome: segmental colectomy (SEG) and total abdo

254 the basis of our results, the possibility of Lynch syndrome should be considered in women with LUS tu

255 Individuals with Lynch syndrome should be encouraged to avoid smoking.

256 LLS than in families with confirmed cases of Lynch syndrome (SIR for Lynch syndrome, 6.04; 95% confid

257 methylation occurs in MSH2 mutation-positive Lynch syndrome subjects or sporadic colorectal cancers (

258 randomized parallel trial, we found that for Lynch syndrome surveillance, high-definition white-light

259 and at-risk family members of pedigrees with Lynch syndrome; Table 10 provides guidelines for screeni

260 rehensive Cancer Network (NCCN) criteria for Lynch syndrome testing (88%; 95% confidence interval [CI

261 RCA2; 93% of these met the NCCN criteria for Lynch syndrome testing and 33% met NCCN criteria for BRC

262 cope of such mutations, and routine clinical Lynch syndrome testing often does not include analysis f

263 all of these patients met NCCN criteria for Lynch syndrome testing.

264 nent, but, other than their association with Lynch syndrome, the contribution of genetic risk factors

265 ry nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome, the hamartomatous polyposis syndromes, a

266 spirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal

267 Salpha and MutLalpha that initiate MMR cause Lynch syndrome, the most common hereditary cancer.

268 y immunohistochemical features suggestive of Lynch Syndrome, though the rapid progression to cancer w

269 Almost all Lynch syndrome tumors have MSI or abnormal IHC and they

270 tissues, including 222 sporadic CRCs and 46 Lynch syndrome tumors that did not express MSH2.

271 idence for frequent MSH2 hypermethylation in Lynch syndrome tumors with MSH2 deficiency.

272 related markers were significantly higher in Lynch syndrome tumors with MSH2 methylation than MSH2-un

273 n 24% (11 of 46) of MSH2-deficient (presumed Lynch syndrome) tumors, whereas no evidence for MSH2 met

274 imited data regarding how well patients with Lynch syndrome understand the clinical implications of g

275 Studying all endometrial cancer patients for Lynch syndrome using a combination of MSI and immunohist

276 ssification of VUSs in genes associated with Lynch syndrome using data collected through both syndrom

277 uspected of the common cancer predisposition Lynch syndrome, variants of unclear significance (VUS),

278 A 50-year-old man affected by Lynch syndrome was referred to our institution for metac

279 a prospective analysis of 386 subjects with Lynch syndrome, we calculated hazard ratios for the asso

280 ive studies of the efficacy of screening for Lynch syndrome, we identified patients with colorectal a

281 om probands referred for genetic testing for Lynch syndrome were analyzed for the presence of large g

282 nted germ-line mutations associated with the Lynch syndrome were identified.

283 A total of 1063 individuals with proven Lynch syndrome were included, 495 male and 568 female (m

284 rs previously reported to be associated with Lynch syndrome were observed, several previously unrepor

285 In the CAPP2 study, individuals with Lynch syndrome were randomly assigned in a two-by-two fa

286 In the CAPP2 randomised trial, carriers of Lynch syndrome were randomly assigned in a two-by-two fa

287 rica, and four [<1%] from The Americas) with Lynch syndrome were randomly assigned to receive 600 mg

288 ariate analysis of variables associated with Lynch syndrome) were compared with tumor MMR testing of

289 Patients were diagnosed with Lynch syndrome when they were found to have pathogenic g

290 y prompts further investigations to diagnose Lynch syndrome, whereas its absence excludes Lynch syndr

291 herited pathogenic variant in the context of Lynch syndrome, which has important implications for fam

292 ontext of the autosomal dominantly inherited Lynch syndrome, which is due to mutations in mismatch re

293 Twenty-one (1.8%) have Lynch syndrome while 106 (9.0%) have somatic hypermethyl

294 risk of developing colorectal cancer due to Lynch syndrome, while indirect evidence indicates that a

295 or women with a mutation associated with the Lynch syndrome who begin regular screening and have risk

296 We describe a 48-year-old woman with Lynch syndrome who was found to have an adenoma with inv

297 Patients at risk for Lynch syndrome with an indeterminate genetic test result

298 Screening for the Lynch syndrome with immunohistochemistry followed by BRA

299 under mutation in Ashkenazi Jews that causes Lynch syndrome, with a prevalence of 0.4%-0.7%.

300 tumors with MMR defects during screening for Lynch syndrome, yet have no identifiable germline mutati